BACKGROUND: A previous survey of physician self-reported practice patterns in the management of CML was conducted in 2005. The National Comprehensive Cancer Network and European LeukemiaNet guidelines now include nilotinib and dasatinib in their treatment algorithms for CML. To assess these new guidelines, a cross-sectional survey of US hematologists and/or oncologists was conducted in December 2010 through an online survey. MATERIALS AND METHODS: The survey had 43 questions consisting of items updated from the 2005 survey to reflect changes in clinical practice, tyrosine kinase inhibitor therapy, and current guidelines. RESULTS: Analysis of the responses from 507 board certified medical oncologists/hematologists suggests that the use of imatinib 400 mg as an initial treatment option had decreased from 62% in 2005 to 52% in the 2010 survey. Currently, nearly 40% of physicians would choose either nilotinib or dasatinib as first-line treatment. From the surveyed physicians, achievement of at least a major molecular response (MMR) is the predominant treatment goal in chronic phase CML. CONCLUSION: This survey emphasizes the need for continued updates and education regarding optimal therapy, monitoring practices, and therapeutic end points in CML. Published by Elsevier Inc.
BACKGROUND: A previous survey of physician self-reported practice patterns in the management of CML was conducted in 2005. The National Comprehensive Cancer Network and European LeukemiaNet guidelines now include nilotinib and dasatinib in their treatment algorithms for CML. To assess these new guidelines, a cross-sectional survey of US hematologists and/or oncologists was conducted in December 2010 through an online survey. MATERIALS AND METHODS: The survey had 43 questions consisting of items updated from the 2005 survey to reflect changes in clinical practice, tyrosine kinase inhibitor therapy, and current guidelines. RESULTS: Analysis of the responses from 507 board certified medical oncologists/hematologists suggests that the use of imatinib 400 mg as an initial treatment option had decreased from 62% in 2005 to 52% in the 2010 survey. Currently, nearly 40% of physicians would choose either nilotinib or dasatinib as first-line treatment. From the surveyed physicians, achievement of at least a major molecular response (MMR) is the predominant treatment goal in chronic phase CML. CONCLUSION: This survey emphasizes the need for continued updates and education regarding optimal therapy, monitoring practices, and therapeutic end points in CML. Published by Elsevier Inc.
Authors: Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jenny Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary B Rios; Hagop Kantarjian Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: P Paschka; M C Müller; K Merx; S Kreil; C Schoch; T Lahaye; A Weisser; A Petzold; H König; U Berger; H Gschaidmeier; R Hehlmann; A Hochhaus Journal: Leukemia Date: 2003-09 Impact factor: 11.528
Authors: Richard D Press; Zac Love; Ashlie A Tronnes; Rui Yang; Thuan Tran; Solange Mongoue-Tchokote; Motomi Mori; Michael J Mauro; Michael W Deininger; Brian J Druker Journal: Blood Date: 2006-02-07 Impact factor: 22.113
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann Journal: Leukemia Date: 2002-11 Impact factor: 11.528
Authors: Jess F Peterson; Nidhi Aggarwal; Clayton A Smith; Susanne M Gollin; Urvashi Surti; Aleksandar Rajkovic; Steven H Swerdlow; Svetlana A Yatsenko Journal: Oncotarget Date: 2015-08-07